Q4FY24
YoY
Revenue +18%
Net profit +87%
HoH
Revenue +8%
Net profit +55%
Expected better revenue growth but the bump in Profits/OPM made up for it.
https://nsearchives.nseindia.com/corporate/FINANCIALRESULTS202324_28052024132456.pdf
Q4FY24
YoY
Revenue +18%
Net profit +87%
HoH
Revenue +8%
Net profit +55%
Expected better revenue growth but the bump in Profits/OPM made up for it.
https://nsearchives.nseindia.com/corporate/FINANCIALRESULTS202324_28052024132456.pdf
I believe Elevation Capital that owned ~20% of the company is winding down the fund. If they’re selling such a large stake via the open market, the stock will remain under pressure until they fully exit.
Outside of Arman, all MFI companies have corrected some 30-40% off highs from last year including Spandana and CreditAccess. I think a lot of people are waiting to hear about regulations from the RBI, and there have been concerns about asset quality in the industry.
I’m using this as an opportunity to add Arman at 2x FY25 BV, and Credit Access at 2.6x FY25 BV, but we’ll only know from numbers / channel checks if the best of the asset quality this cycle is behind us.
D: invested, transactions in the last 30 days.
Nothing to do with fundamentals 1950 is strong support profit booking is happening
@stuti_agarwal and @Jadewade I think the reason is to allow to reach 50% of the recent ATH to allow for the 1:1 bonus share issue about to happen. As the number of shares is about to be doubled, the CMP of the share will reach around half when the bonus issue happens. The voting is not yet done and an extraordinary general meeting has been called.
This is what my understanding is. The market is overshooting and expecting the vote to go through and adjusting for that.
Just to add apart from generic flovent and ryaltris, the next 2 drugs will be envafolimab and winlevi. One more pmdi like flovent to be filed in fy 25 and launched in fy 26.
GPL is the only filer in flovent and market size of all doszge is 1.6 bn usd. Gpl as of now has filed for only 1 dosage, balance under process.
Hi, this company is running a very interesting model - they own the distribution channel themselves to whom they present significantly longer working capital cycle than any building materials companies. Then secondly they give these channel partners a 10-15% of sales as discounts/benefits yet for some reason growth guidance is tepid. They somehow need cash to keep the channel happy but the channel is owned by them? Open to interpretation but capital allocation here is questionable.
Overall, results do seem good. They have met guidance across all key metrics.
Only 2 minor concerns:
Note - Tracking as a potential investment candidate. So my views are biased.
trade receivables is also increasing very rapidly. could be a red flag to monitor
Market did not react positively even though the stock was moving sideways for some time. Can experts comment what could be concerns of market?
Disc: took a 0.7% position today and thinking pf increasing this high growth low NNPA NBFC
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Latest Stock Market News
The Most Valuable Commodity Is Information!